Validation of prognostic factors and survival of patients with multiple myeloma in a real-life autologous stem cell transplantation setting: a Swiss single centre experience

Abstract

ASCT is a safe and effective treatment mode in eligible patients with MM. TRM was below average at our institution. Achievement of CR after transplantation was the most valuable predictor for improved overall survival.

Gender-Specific Aspects in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Single-Center Experience

“…Different prognostic factors in MM patients undergoing ASCT were investigated in a retrospective single-center analysis, but gender did not show a statistically significant difference between female and male patients according to median OS ( p = 0.13) [21] . These results are in keeping with another single-center analysis in which gender was not associated with a worse event-free survival and OS ( p = 0.69 and p = 0.97, respectively) [14] .…”

“…The same observation was reported in a retrospective study by a Swiss group. No statistical significances were observed between females and males in terms of event-free survival and OS ( p = 0.69 and p = 0.97, respectively) [14] . No statistically significances could be observed in another study by Min et al [13] : in patients aged between 65 and 70 years gender did also not play a statistically significant role between female and male patients ( p = 0.9031) [12] .…”

“…In a study by Ozaki et al [12] , gender was not a statistically significant parameter in terms of overall survival (OS) ( p = 0.9031), and the same observations could be demonstrated in another study [13] . In a retrospective analysis of a Swiss study group, gender did not play a statistically significant role [14] . We performed a retrospective single center analysis of 191 MM patients undergoing ASCT to assess potential differences between female and male patients.…”

Modified CVAD and modified CBAD compared to high‐dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma

“…Although more patients in the Cy group than in either the mCVAD or mCBAD groups achieved a PR or better at day 100 post‐transplantation, this difference is probably a reflection of the advanced disease status of the latter two groups, especially in the mCBAD group. Similarly, patients in the mCBAD group had a shorter PFS and OS, which again highlights a more advanced disease and a shorter median follow‐up in these patients, which is in accordance with recent studies on the impact of pretransplant disease status on prognosis …”

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies

“…In the same way, the R‐ISS was tested in patients of different ages (≤65 and >65 years) and in patients receiving different treatments (ASCT, proteasome inhibitors [PIs], or immunomodulatory drugs [IMiDs]) 1. Although the ISS risk stratification tool has been evaluated outside of a clinical trial framework,14 the majority of patients (69.1%) on which the system was based were participating in a clinical trial10; similarly, the R‐ISS was based wholly on patients enrolled in experimental trials 1. This is relevant because patients in cancer trials may not be representative of the overall patient population and derivation of risk stratification criteria based on a highly selected set of patients may limit their applicability in the real world.…”